NeuroQuest is developing NeuroScreen®, a novel blood-based diagnostic test for the early detection of Alzheimer’s disease. The test uses proprietary immune-system biomarkers and advanced algorithms to identify and quantify amyloid-β accumulation in the brain, enabling detection years before the onset of clinical symptoms. By providing an accurate, affordable, and minimally invasive alternative to PET scans and cerebrospinal fluid testing, NeuroQuest aims to expand access to early diagnosis and improve the effectiveness of emerging disease-modifying therapies.